IJGC conversations

Revisited: ESGO/INCIP 2025 Guidelines for Cancer in Pregnancy with Frédéric Amant

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Frédéric Amant to discuss ESGO/INCIP 2025 Guidelines for Cancer in Pregnancy.
 
Frédéric Amant (MD, PhD) received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998 and his subspecialty training in gynecologic oncology in 2000. He defended his thesis on uterine sarcomas in 2002 at the KU Leuven. He is specialist at the UZ Leuven in Belgium. He is professor at the KU Leuven in Belgium and at the University of Amsterdam in the Netherlands, and honorary professor at the university of Pretoria, South Africa. Since 2024 he is council member of the European Society of Gynecologic Oncology.
Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven, Belgium and at the Netherlands Cancer Institute. In 2005 he founded the “International Network on Cancer, Infertility and Pregnancy” (INCIP)(www.cancerinpregnancy.org), and chairs this network up till now. Since 2014, INCIP also registers young women who aim to preserve their fertility. In 2021 he launched the Advisory Board Cancer Infertility Pregnancy (ABCIP) under the umbrella of INCIP. In addition, Frédéric Amant founded Trace, the tumor xenograft platform at the KU Leuven and the Fund for Innovative Research at the KU Leuven. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer. Since 2024 he is member of the research council at the KU Leuven.

SUROVA Study: Surgery vs Neoadjuvant Therapy in Ovarian Cancer with Luis Chiva

In this IJGC podcast, Dr. Pedro Ramirez discusses SUROVA Study: Surgery vs Neoadjuvant Therapy in Ovarian Cancer with Luis Chiva.
 
Prof. Luis M. Chiva, MD, PhD, is Chair of Obstetrics and Gynecology and Professor of Gynecology and Medical Ethics at the University of Navarra in Pamplona, Spain. An internationally recognized leader in gynecologic oncology, he is renowned for his expertise in complex pelvic oncologic surgery and his commitment to advancing surgical quality and patient-centered care.
A graduate of the University of Madrid, Dr. Chiva completed his gynecologic oncology fellowship at Rush-Presbyterian–St. Luke’s Medical Center in Chicago. He later directed the Gynecologic Oncology Department at MD Anderson Cancer Center Madrid and established educational collaborations with MD Anderson Houston.
Dr. Chiva has authored over 100 peer-reviewed publications, delivered more than 300 invited lectures, and spearheaded key educational initiatives such as the international “Meet the Surgeon” program. He has held major leadership roles within ESGO, including serving as council member, chair of the Quality Assurance and Certification Committee, and Editor-in-Chief of the ESGO e-Academy platform. He was presented for Honorary Fellowship in the American College of Surgeons in 2021.  

Updates in Radiotherapy in Gynecologic Cancers with Junzo Chino

In this IJGC podcast, Dr. Pedro Ramirez discusses Updates in Radiotherapy in Gynecologic Cancers with Junzo Chino.
 
Dr. Chino is an Associate Professor of Radiation Oncology and Director of Brachytherapy at the Duke Cancer Center. He has authored over 100 publications in the peer reviewed literature, and his research interests are concentrated in radiation therapy for gynecologic cancer, as well as health services and disparities. He was lead author of the ASTRO guidelines task force for cervical cancer, and served as the GYN section editor at the International Journal of Radiation Oncology Biology and Physics and Associate Editor of the International Journal of Gynecological Cancer. His recent article published in Cancer focuses on Recent advances in gynecologic radiation oncology. 

IJGC conversations 2025 November Editor's Choice

In this episode of the IJGC conversations 2025 November Editor's Choice, Editorial Fellow Paula Mateo-Kubach and Matteo Loverro discusses the contents of the 2025 November issue of IJGC. 
 

Results of the MoST-CIRCUIT Trial with Oliver Klein

In this IJGC podcast, Dr. Pedro Ramirez discusses Results of the MoST-CIRCUIT Trial with Oliver Klein.
 
A/Prof Klein is a clinician-scientist at the Austin Hospital and the ONJCRI with a 20-year experience in the field of cancer immunotherapy and a particular interest in the treatment of rare gynaecological malignancies. Dr Klein pioneered clinical trials using checkpoint blockade in patients with advanced rare cancers including gynaecological malignancies. These trials demonstrated unprecedented clinical outcomes in this patient population of major unmet medical need. Next to his clinical research, Dr Klein participates and leads translational research investigating biological correlates of response to immunotherapy.

Addition of Metronidazole to Prevent SSI with Megan Gorman and Marina Frimer

In this IJGC podcast, Dr. Pedro Ramirez discusses Addition of Metronidazole to Prevent SSI with Megan Gorman and Marina Frimer.
 
Dr. Marina Frimer is a gynecologic oncologist and physician-scientist whose work bridges clinical innovation and translational research in gynecologic malignancies. As Associate Professor at the Zucker School of Medicine at Hofstra/Northwell and Associate Chief for Research and Academic Development at Northwell Health, she plays a key role in advancing academic and clinical research programs in women’s cancer.Dr. Frimer’s research focuses on improving surgical and therapeutic outcomes in gynecologic oncology, with a particular emphasis on uterine and endometrial cancers. Her recent publications include a phase II clinical trial investigating niraparib maintenance therapy in uterine serous carcinoma (BMJ Open, 2025), studies on perioperative antibiotic optimization for hysterectomy in gynecologic malignancies (Int J Gynecol Cancer, 2025), and patient-derived organoid models of endometrial cancer (Bio Protoc, 2024).
 
Dr. Frimer has contributed to influential studies on DNA repair mechanisms, endometrial microbiome, and racial disparities in endometrial cancer. Her work has been published in leading journals such as Gynecologic Oncology, JCO Precision Oncology, and International Journal of Gynecological Cancer, and she has collaborated extensively on multi-institutional and translational research initiatives.Dr. Frimer is recognized for her leadership in mentoring early-career investigators and promoting clinical trial development within Northwell’s gynecologic oncology research program.
 
Dr. Megan Gorman is a gynecologic oncologist and Assistant Professor at Thomas Jefferson University Hospital in Philadelphia, PA.  Dr. Gorman completed her medical education at the Warren Alpert Medical School of Brown University, her training in obstetrics and gynecology at Stony Brook University Hospital, her fellowship in gynecologic oncology at Zucker School of Medicine at Hofstra/Northwell Long Island Jewish Medical Center. Her recent clinical research in gynecologic malignancies focuses on racial disparities in cancer care, improved surgical outcomes, funding disparities in research,  the role of next generation sequencing, novel therapies, end of life care, and hormone replacement in survivorship. She has also collaborated on translational research initiatives including the development of a patient-derived organoid model of endometrial cancers. Dr. Gorman is passionate about resident education, promoting health literacy, and the treatment of HPV-associated malignancies, and recently completed her second medical mission in Salima, Malawi. 

Checkpoint Inhibitor Rechallenge in Endometrial Cancer with Brian Slomovitz

In this IJGC podcast, Dr. Pedro Ramirez discusses Checkpoint Inhibitor Rechallenge in Endometrial Cancer with Brian Slomovitz.
Dr. Slomovitz is a Gynecologic Oncologist at Mount Sinai Medical Center in Miami Beach, Florida, and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.
 
 

PEACOCC Trial: Pembrolizumab in Clear Cell Cancer with Rebecca Kristeleit

In this IJGC podcast, Dr. Pedro Ramirez discusses PEACOCC Trial: Pembrolizumab in Clear Cell Cancer with Rebecca Kristeleit.
 
Rebecca Kristeleit is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and an Adjunct Associate Professor in the Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences at KCL, London. She is Research Lead for gynaecological cancer, R&D Lead for Oncology and Clinical Lead for Oncology and Haematology Clinical Trials at Guy’s and St Thomas’ NHS Foundation Trust. She works as a Principle Investigator within the KCL Cancer Early Phase Trials Unit, Theme Lead within King’s Health Partners ECMC and is Academic Lead for the King’s Health Partners Gynaecological Cancer Biobank.  Rebecca has extensive experience in experimental therapeutics and associated translational research, particularly molecular selection for therapeutics, as well as Phase II and III clinical trials. She works closely with several academic collaborators at KCL, nationally and internationally. She is currently leading two trial programmes of drugs discovered at KCL, a novel immunotherapy and a solid tumour CAR-T. She mentors and supervises KCL undergraduate and postgraduate students. Rebecca’s primary motivation is to improve treatment options available for patients with gynaecological cancer and she has been instrumental in the development and delivery of new licensed drugs in gynaecological cancer, for example rucaparib, dostarlimab, through clinical trial research leadership. She led the UK academic PEACOCC trial investigating pembrolizumab in clear cell gynaecological cancer and is global Co-Investigator for DOVE, a follow-on international randomised Phase II trial in the same rare indication. She leads many trials nationally and internationally, several in partnership with GTG-UK. Rebecca has published extensively, speaks regularly at International Conferences and has held several national and international research leadership positions including Chair BGCS Scientific Committee, BGCS guidelines committee, BGCS medical oncology representative, Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, CRUK New Agents Committee, ESMO Faculty, Chair ASCO Gynaecological Cancer Scientific Committee, ASCO educational committee.

ADCs and Oral Mucositis with Michelle D.S. Lightfoot

In this IJGC podcast, Dr. Pedro Ramirez discusses ADCs and Oral Mucositis: Strategies for Gynecologic Oncologists with Michelle D. Lightfoot.
 
Michelle D. Lightfoot, MD, joined NYU Langone in August 2021 after completing fellowship training in gynecologic oncology at The Ohio State University. She received her medical degree from Harvard Medical School and a master’s in public health from Columbia University’s Mailman School of Public Health, before completing residency training at Beth Israel Deaconess Medical Center/Harvard Medical School.
At NYU Langone’s Perlmutter Cancer Center and Bellevue Hospital, Dr. Lightfoot provides clinical care and is committed to training future generations of physicians and gynecologic oncologists. As a physician–researcher, she is dedicated to improving care for women with gynecologic malignancies through research, quality improvement initiatives, and public health measures. She also serves on the Society of Gynecologic Oncology’s policy, quality, and outcomes subcommittee.
In collaboration with researchers at NYU Langone Health’s Institute for Excellence in Health Equity, Dr. Lightfoot’s research focuses on identifying and eliminating disparities in cancer care delivery and outcomes among women with gynecologic cancers

IJGC conversations 2025 October Editor's Choice

In this episode of the IJGC conversations 2025 October Editor's Choice, Editorial Fellow Tommaso Meschini and Carlotta Sabini discusses the contents of the 2025 October issue of IJGC.